Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
about
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceDown-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicityManganism in the 21st century: the Hanninen lectureEnhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SLRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriersThe role of biomarkers and imaging in Parkinson's disease.Neuroimaging in pre-motor Parkinson's diseaseNeuroimaging: current role in detecting pre-motor Parkinson's disease.Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptakeReorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applicationsImaging in Parkinson's disease: time to look below the neck.Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.LRRK2 in Parkinson's disease: genetic and clinical studies from patients.Milestones in neuroimaging.Moving forward: advances in the treatment of movement disorders with deep brain stimulation.Biomarkers for trials of neuroprotection in Parkinson's disease.Biomarkers of Parkinson's disease: current status and future perspectives.Functional neuroimaging in Parkinson's disease.Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.Neuroimaging in the early diagnosis of neurodegenerative disease.Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in miceApplication of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.
P2860
Q24293070-07DFD478-CCC2-4DCA-890C-77E33A9F1B29Q24339471-D3808BF5-F1CD-49E4-8764-F80D529854EFQ27015750-22A149CF-5D46-4E39-BAB7-CC1B6340BC2DQ28589899-2CC0203E-6E65-4054-BFA0-71D7DAF4B944Q30524899-F277CB1D-53D0-4959-91D4-BEA312E95F01Q30525550-83190F56-1501-412D-A656-27AEEEB45A55Q31041660-3E352A4B-D3C8-4913-84FE-0912DDC2FF7BQ33676222-0C132B17-77E9-4CBB-93DD-1438F779E709Q34234625-6E1279C4-954F-436A-8B62-283DEC6DBDBAQ34242682-51DE4600-2E65-41D6-9D6A-9775DBC46D10Q34267681-A1151E6E-B557-427C-BC84-D2A9A70080C1Q35059247-E604D2BB-35A3-4A79-9681-FA81A9545F7FQ35106295-6ED6AB5F-C337-4BEA-BF70-ADAE682E8308Q35148581-FC7A7550-8F48-425F-90BE-E425E913DD27Q35533959-2D9922B6-591D-4686-B002-D7668BEB30AEQ36553302-30E9A48D-11DE-4A89-B5A6-EF841D48B0D2Q36972794-3257CDFF-B723-4724-9618-8DED240E1C2CQ37608624-53B558C3-92A5-4304-BC57-5E438EE155FDQ37882576-8F1EDD4C-C41C-4A6A-91A1-ACCC98F986F9Q37956311-4B0B62CD-F109-4618-AE3B-063AC931C628Q38038544-2AB1AC24-AE2E-46E5-B98A-2671D8C5A3ACQ38043841-35617606-A28B-4872-B2AF-FDEA50F58113Q38088371-6DCDC84B-C26C-43A4-ACEC-F12244CFEE19Q38881337-BEF3B4F2-76AE-4F4D-97AF-707295B7A682Q42043633-3FBF849E-6661-4901-91B9-E804FF32116BQ42268862-C50622C8-C641-4E91-A8E3-49A548F3869FQ42353561-BDFD5A4E-2677-468A-A4F8-3633D6AEAC18Q42495787-656AA928-4D3E-4F2F-8525-A3F1FC14D731Q43143708-18DB138F-83C5-4036-88CD-1EC5FA3D9F41Q44060284-0DE2A7F3-C5A1-45DA-9B76-85CE5BECA2D7Q47907932-CDE0C27F-AF6B-4217-9494-276098D6212AQ49886566-CF3348BD-0284-4E89-9C95-B8C5A3114CF4Q53386963-5005624C-7C62-41A3-91EC-93B5E718E574Q55037516-418EA5B9-6FAD-4399-928F-427E96F8F2D9Q55287139-BEE0CE5B-C0C5-4846-9ABF-E0B58BE5932A
P2860
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@ast
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@en
type
label
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@ast
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@en
prefLabel
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@ast
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@en
P2093
P2860
P1433
P1476
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.
@en
P2093
A J Stoessl
A Strongosky
J McKenzie
M J Farrer
M Schulzer
R Nandhagopal
S McCormick
P2860
P304
P356
10.1212/01.WNL.0000335973.66333.58
P407
P577
2008-11-01T00:00:00Z